Abstracts Archive - Page 570 of 1683 - ATC Abstracts

2019 American Transplant Congress
Adjunctive Therapy With Tocilizumab For Treatment Of Acute Antibody Mediated Rejection – 2 Year Experience
K. Venkatachalam, R. Delos Santos, B. Heady, A. Malone, T. Alhamad
Washington University, St. Louis, MO
*Purpose: Reporting our center's experience in use of tocilizumab for treatment of antibody mediated rejection*Methods: We have previously reported the efficacy of Tocilizumab (TCZ), an…
2019 American Transplant Congress
Do Outcomes Differ in Glomerulitis Predominant Antibody Mediated Rejection and Peritubular capillaritis Predominant Antibody Mediated Rejection?
S. Sethi¹, J. Hou², M. Lin², Y. Ren², A. Peng¹, R. Najjar¹, A. Vo¹, S. Jordan¹, M. Haas², E. Huang¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA, ²Pathology, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: The diagnosis of antibody-mediated rejection (ABMR) in renal allografts requires microvascular inflammation in the form of glomerulitis or peritubular capillaritis (g>0 and/or ptc>0). We…
2019 American Transplant Congress
Peritubular Capillary C4d Positivity in Renal Allograft Biopsies: Implications for Allograft Survival
A. Bailey, S. Tremblay, A. R. Shields, J. Wang, R. Alloway, E. S. Woodle
Transplant Surgery, University of Cincinnati, Cincinnati, OH
*Purpose: C4d deposition in the peritubular capillaries (PTCs) is associated with acute antibody mediated rejection (AMR) and reduced renal allograft survival. PTC C4d positivity, however,…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients
R. D. Swinford¹, A. M. De Golovine¹, C. Bell¹, A. Pai¹, A. R. Edwards¹, S. Connor², J. S. Bynon¹
¹Pediatrics, UTHealth, McGovern Medical School, University of Texas at Houston, Houston, TX, ²Transplantation, Memorial Hermann Hospital, Houston, TX
*Purpose: Accurate identification of successful treatment for rejection (R) without repeat kidney biopsy (KB) in kidney transplantation is an unmet need. The few existing biomarkers…
2019 American Transplant Congress
Use of Eculizumab for Active Antibody-Mediated Rejection That Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases
E. Tan¹, B. J. Andrew², P. G. Dean², M. F. Shaheen¹, M. D. Stegall², C. A. Schinstock²
¹Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN, ²The William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic Rochester, Rochester, MN
*Purpose: Active antibody-mediated rejection (ABMR) that occurs during the amnestic response within the first month post-transplant is a rare but devastating cause of early allograft…
2019 American Transplant Congress
Is HLA Donor-Specific Antibody (DSA)-C3d+ Assay a Potential Predictor of Subclinical Antibody Mediated Damage in the Renal Graft?
A. G. Contreras¹, M. I. Solis-G¹, C. Ramirez-Espinoza¹, J. Hernandez-Rosales², M. Vilatoba-Chapa¹, R. Cruz-Martínez¹, J. Granados¹, L. E. Morales-Buenrostro³, J. Alberú¹, J. M. Arreola-Guerra⁴
¹Transplantation, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ²Department of Histocompatibility, Laboratorio Clinico del Campestre, Mexico City, Mexico, ³Nephrology-Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ⁴Internal Medicine, Centenario Hospital Miguel Hidalgo, Mexico City, Mexico
*Purpose: The Aim of the study was to explore the predictive value of the C3d assay for tissue damage in kidney transplant recipients (KTR) in…
2019 American Transplant Congress
Induction Therapy Modulated by the Absence of Preformed Donor-Specific Antibodies (DSAS) Regardless of the Level of Sensitization
M. Cristelli, K. Linhares, R. de Marco, L. Viana, C. Felipe, M. Gaspar, C. Peixoto, G. Marcelo Gomes, J. Toniato Rezende, K. Nunes Ficher, L. Alfaro Villanueva, V. Lima, M. Gerbase de Lima, J. Medina Pestana, H. Tedesco Silva Junior
Núcleo de Ensino e Pesquisa, Hospital do Rim, São Paulo, Brazil
*Purpose: We hypothesized that sensitized patients with preformed DSAs other than anti-HLA A, B, DR could receive less intensive induction therapy.*Methods: Single center retrospective cohort…
2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
D. Salerno¹, N. Lange¹, E. Simoneau², C. Sammons³, D. Bley¹, R. S. Brown Jr⁴, J. Emond², K. Halazun⁵
¹Pharmacy, NewYork-Presbyterian Hospital, New York, NY, ²Surgery, Columbia University Irving Medical Center, New York, NY, ³Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Medicine, Weill Cornell Medicine, New York, NY, ⁵Surgery, Weill Cornell Medicine, New York, NY
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…
2019 American Transplant Congress
Long Term Outcomes of Patients Transplanted for Hepatocellular Carcinoma with Human Immunodeficiency Virus Infection
R. Gedaly-Eidelman, E. Chacon, P. Eman, M. Gupta, J. Berger, A. El-Husseini, X. Mei, F. Marti, L. Turcios, M. Shah
University of Kentucky, Lexington, KY
*Purpose: Several studies have reported that HIV+ patients are 4-6 times more likely to develop HCC than uninfected individuals. Our aim was to assess outcomes…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
M. Najjar¹, K. Bruestle¹, P. Jiang¹, E. Lieberman¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein², T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival…